Chiome Bioscience Inc. (TYO:4583)

Market Cap	9.89B
Revenue (ttm)	789.86M
Net Income (ttm)	-982.82M
Shares Out	67.76M
EPS (ttm)	-15.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,800,500
Average Volume	1,195,635
Open	138.00
Previous Close	138.00
Day's Range	137.00 - 146.00
52-Week Range	75.00 - 304.00
Beta	0.27
RSI	58.43
Earnings Date	May 12, 2025

About Chiome Bioscience

Chiome Bioscience Inc. engages in the research and development of drug discovery technology platforms worldwide. The company operates through two segments, Drug Discovery Business and Drug Discovery Support Business. It offers ADLib System, a monoclonal antibody generating system for drug discovery and development; and Human ADLib System, which converts chicken antibody genes to humanized antibodies. The company also provides protein expression and purification services; stable cell line development services for recombinant protein and antibody...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 53
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4583

Financial Performance

In 2024, Chiome Bioscience's revenue was 780.81 million, an increase of 14.41% compared to the previous year's 682.46 million. Losses were -1.02 billion, -16.33% less than in 2023.